Solutions albuterol inhalation

083% contains 0.83 mg albuterol (as 1.0 mg albuterol sulfate) in an isotonic aqueous solution containing sodium chloride and benzalkonium chloride sulfuric acid is used to adjust the pH between 3 and 5. The 0.083% solution requires no dilution before administration by nebulization. PROVENTIL Inhalation Solution 0.083% contains no sulfiting agents. It is supplied in 3-mL HDPE bottles for unit-dose dispensing. 

AccuNeb (albuterol sulfate) inhalation solution is supplied in two strengths in unit-dose vials. Each unit-dose vial contains either 0.75 mg of albuterol sulfate (equivalent to 0.63 mg of albuterol) or 1.50 mg of albuterol sulfate (equivalent to 1.25 mg of albuterol) with sodium chloride and sulfuric acid in a 3-mL isotonic, sterile, aqueous solution. Sodium chloride is added to adjust isotonicity of the solution, and sulfuric acid is added to adjust the pH of the solution to 3.5. 

Charge all items in a suitable stainless steel vessel and mix. Keep nitrogen flushing through- 

---

ALBUTEROL SULFATE INHALATION SOLUTION 20ML BOTTLE WITH DROPPER 6505012579963 BT 10 41 ... 

Rx Albuterol sulfate and ipratropium bromide inhalation solution ... 

Inhalation solutions are designed to deliver a drug into the respiratory tree of a patient for a local or systemie effect. Examples of compounded inhalation solutions (Table 9) include individually and in combinations of albuterol, cromolyn, morphine sulfate, corticosteroids, ipratropium, metaproterenol, terbutaline, and others. 

Solution incompatibility Advise patients that ipratropium inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within 1 hour. 

Inhalation solution 0.5 mg ipratopium bromide and 3 mg albuterol sulfate (equiv. to 2.5 mg albuterol base) DuoNeb (Dey)... 

Albuterol (also known as salbutamol outside the United States), the most commonly used inhaled short-acting 132-agonist, is a racemic mixture (50 50) of albuterol enantiomers. The R-enantiomer is the active component whereas the S-enantiomer is inactive or may be associated with unwanted effects. Levalbuterol, the pure R-enantiomer of albuterol, is available as a solution for nebulization and as an MDI dosage form. Comparative studies show similar efficacy and safety between levalbuterol and albuterol, but the acquisition cost of levalbuterol is substantially higher. 

Inhalation - Safety and efficacy for use of bitolterol, pirbuterol, isoetharine, salmeterol, and terbutaline in children 12 years of age and younger have not been established. Albuterol aerosol in children younger than 4 years of age and albuterol solution for inhalation in children younger than 2 years of age have not been established. Metaproterenol may be used in children 6 years of age and older. 

Inhalant 90 mcg/puff aerosol 0.021, 0.042, 0.083, 0.5, 0.63% solution for nebulization Oral 2,4 mg tablets 2 mg/5 mL syrup Oral sustained-release 4, 8 mg tablets Albuterol/Ipratropium (Combivent, DuoNeb)... 

Inhalant 103 meg albuterol + 18 meg ipratropium/puff 3 mg albuterol + 0.5 mg ipratropium/3 mL solution for nebulization Arformoterol (Brovana)... 

Albuterol is available as tablets and as syrup for oral use, as solution and as sulfate for inhalation, as... 

Antibiotics should be used only with the development of bacterial bronchitis or pneumonia. jS-adrenergic agonist has been used to relieve bronchospasm by relaxing bronchial smooth muscle and reducing hyperactivity in diphosgene inhalation. An adult dose of albuterol 0.5% (2.5 mg in 2.5 ml saline solution) can be used and repeated as needed. 

The most significant developments in metered-dose inhaler technology to occur since the early 1990s have been the introduction of hydrofluoroalkane (HFA) systems as alternatives to chlorofluorocarbon (CFC) systems [174]. This has largely been caused by the link between the use of CFC systems and ozone depletion in the upper atmosphere [152,175]. Albuterol and beclomethasone have been reformulated in HFA products, but as yet the CFC products are still subject to an annually renewable medical exemption. The Food and Drug Administration has recently published its position on alternative propellant formulations, which should initiate the phase-out of CFCs [176]. In the meantime, a number of generic CFC products of albuterol have been manufactured. The opportunity for reformulation of products as they come of patent is likely to increase research and development in this area in the near future. New formulation opportunities will also arise from these developments, including solutions [177], micellar [178,179], and microemulsion [180]. 

Inhaled antichohnergic therapies have an important role in the management of COPD. Ipratropium is available as an MDl (individually and in combination with albuterol) dehvermg 18 meg per puff and as a solution for nebuhzation at 200 mcg/mL. Tiotropinm is available as a DPI at 18 meg per dose. Tiotropinm became available in rnid-2004. However, based on efficacy and convenience, it hkely will play a major role in COPD management. 

Albuterol has the N-f-butyl and a salicyl alcohol phenyl ring, which gives it optimal P2-selectivity. It is resistant to COMT and slowly metabolized by MAO, giving it good oral bioavailability. Its onset by inhalation is within 5 minutes, with a duration of action between 4 and 8 hours. It currently is the drug of choice for relief of the acute bronchospasm of an asthmatic attack. Levalbuterol is the f -(-)-isomer of albuterol and is available only in solution to be administered via nebulizer. Because it is the active isomer, the dose is fourfold less than that of albuterol. 

Pirbuterol is the pyridine isostere of albuterol. It has pharmacokinetics similar to albuterol but is half as potent at the p2-receptor. Pirbuterol is only available as an inhaler, whereas albuterol comes in tablet, syrup, solution, and aerosol formulations. Adverse effects of pirbuterol are nervousness, tremor, and headache, which is less than the profile for albuterol, which adds nausea, vomiting, dizziness, hypertension, insomnia, tachycardia, and palpitations. 

In 1999, the R-enantiomer of albuterol, levalbuterol, received approval from the US Food and Drug Administration for the treatment or prevention of bronchospasm. A number of recently published clinical studies have demonstrated the effectiveness of inhaled levalbuterol solution, delivered using a nebulizer, in the treatment of patients with mild to moderate asthma [109 111]. The dose of levalbuterol required to produce a significant bronchodilatory response is equivalent to 50% of the dose of the racemate. Consequently, the effect of levalbuterol on heart rate and potassium levels is substantially lower than that observed after the administration of therapeutic doses of the racemate, presumably owing to the absence of the S enantiomer [109]. 

Figure 11 inhaled mass versus time for a solution (albuterol) and a suspension (budesonide) using the AeroTech II nebulizer (tidal volume, 200 mL frequency, 25 breaths per min duty cycle, 0.5). 

---